Results Case report A 35-year-old female with GH-secreting pituitary tumors was treated with surgery and medical therapy using the first-generation SSA, octreotide, and the D2 agonist, cabergoline
Needle-phobic patients who want an evidence-backed oral GLP-1 (Wegovy pill)
Tune in to Primes Pharmacy Friends podcast episode on MASH to learn more
The TriNetX platform has been used in retrospective cohort studies [25,26,27,28,29,30,31,32,33,34,35,36,37,38] including evaluating risk and health outcomes of patients with substance use disorders including CUD [25, 32, 35] and the associations of GLP-1RAs with cancer [37] and semaglutide with suicidal ideations [38]
Novo Nordisk was also developing FGF21 drug zalfermin as a MASH treatment, but discontinued the programme after concluding that it did not show significant differentiation from semaglutide in efficacy.